5/20/2022 8:19:00 AM
Lilly : CHMP Issues Positive Opinion For OLUMIANT For Treatment Of Adults With Severe Alopecia Areata
5/11/2022 6:51:49 AM
Lilly And Incyte: FDA Approves OLUMIANT For Certain Hospitalized Patients With COVID-19
5/3/2022 7:10:46 AM
Incyte Q1 GAAP EPS $0.17; Non-GAAP EPS $0.55
2/8/2022 7:08:02 AM
Incyte Q4 GAAP EPS $2.54; Non-GAAP EPS $0.10
12/11/2021 12:06:52 PM
MorphoSys Announces Additional Results From RE-MIND2 Study Of Tafasitamab - Lenalidomide For DLBCL
11/9/2021 8:32:46 AM
Lilly : OLUMIANT Long-Term Safety Profile Established Up To 9.3 Years In Analysis On Rheumatoid Arthritis